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Mutations in SNX14 Cause a Distinctive
Autosomal-Recessive Cerebellar Ataxia
and Intellectual Disability Syndrome
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Intellectual disability and cerebellar atrophy occur together in a large number of genetic conditions and are frequently associated with
microcephaly and/or epilepsy. Here we report the identification of causal mutations in Sorting Nexin 14 (SNX14) found in seven affected
individuals from three unrelated consanguineous families who presented with recessively inherited moderate-severe intellectual
disability, cerebellar ataxia, early-onset cerebellar atrophy, sensorineural hearing loss, and the distinctive association of progressively
coarsening facial features, relative macrocephaly, and the absence of seizures. We used homozygosity mapping and whole-exome
sequencing to identify a homozygous nonsense mutation and an in-frame multiexon deletion in two families. A homozygous splice
site mutation was identified by Sanger sequencing of SNX14 in a third family, selected purely by phenotypic similarity. This discovery
confirms that these characteristic features represent a distinct and recognizable syndrome. SNX14 encodes a cellular protein containing
Phox (PX) and regulator of G protein signaling (RGS) domains. Weighted gene coexpression network analysis predicts that SNX14 is
highly coexpressed with genes involved in cellular protein metabolism and vesicle-mediated transport. All three mutations either
directly affected the PX domain or diminished SNX14 levels, implicating a loss of normal cellular function. This manifested as increased
cytoplasmic vacuolation as observed in cultured fibroblasts. Our findings indicate an essential role for SNX14 in neural development and
function, particularly in development and maturation of the cerebellum.Intellectual disability (ID) syndromes with a small cere-
bellum constitute a clinically and genetically heteroge-
neous group of neurological disorders for which the under-
lyingmolecular etiology is diverse and established in only a
small subset. Several different cellular mechanisms have
been implicated including mutations in SIL1, coding for
an endoplasmic reticulum resident cochaperone, which
cause Marinesco-Sjogren syndrome (MSS [MIM 248800]);1
sialic acid disorders such as Salla disease (MIM 604369);2
disorders of peroxisome biogenesis in atypical Refsum dis-
ease (MIM 614879);3 congenital disorders of glycosylation,
especially type 1a caused by mutations in PMM2 (MIM
212065);4 and the X-linked ID-small cerebellum syndrome
caused by mutations in OPHN1 (MIM 300486), a Rho-
GTPase-activating protein (GAP).5 Related phenotypes
include the group designated as pontocerebellar hypopla-
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The Americana number of genes involved in tRNA biogenesis (including
RARS2 [MIM 611523], TSEN54 [MIM 225753], TSEN34
[MIM 612390], TSEN2 [MIM 612389], and CLP1 [MIM
615803]),6–10 in rRNA processing (the exosomal genes
EXOSC3 [MIM 614678] and EXOSC8 [MIM 606019]),11,12
and another (CHMP1A [MIM 614961]), with a dual role in
protein sorting at the endosome and chromatin modifica-
tion at the nucleus.13 Other cellular processes include syn-
aptic and cell junction function (CASK [MIM 300749]),14
cell cycle progression, and cell division (the serine-threo-
nine kinase VRK1 [MIM 607596]).15 At the biochemical
level, it is not clear how disruption of many of these genes
leads to hindbrain hypoplasia or atrophy. The classification
and diagnostic approach of cerebellar disease associated
with ID in childhood is complex and challenging, often de-
pending on the careful identification and assessment of
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Figure 1. Phenotype of Affected Individuals from the Three Families Presented
Photographs and brainMRI scans from family 1 individual IV.3 aged 19 years (A) and 22 years (E); family 1 individual IV.6 aged 6 years (B,
F) and 7 years (I, I0); family 2 individual V.1 aged 4.5 years (C, G, J, J0); family 3 individual III.2 aged 22 years (D, H) and 10 years (K, K0);
and family 2 individual V.2 aged 9 months (L, L0). Notice the similar facial features mainly characterized by broad face, fullness of the
upper eyelid, broad nasal base and slight underdevelopment of the alae, broad and long philtrum, thick lower lip vermillion, and fifth
finger brachycamptodactyly. In the first years of life, no neuroradiological anomalies were observed in affected individuals, as depicted
here by the normal T1-weightedmid-sagittal (L) and coronal (L0) MRI sections, which have not yet been repeated for this individual. MRI
images performed for other individuals during infancy are unavailable but were reported to be normal. At older ages, affected individuals
have a small cerebellum with thin folia and enlarged fissures, suggestive of global cerebellar atrophy as shown here in the T1-weighted
MRI images from three of the children, one from each family (mid-sagittal sections I–K; coronal sections I0–K0). The pons appear small but
in comparison are well preserved.We recently described an autosomal-recessive condition
in a consanguineous Portuguese family (family 1) in which
two sisters (Figures 1 and 2A) share a similar phenotype,
characterized by severe cerebellar ataxia, severe intellectual
disability (ID), absent speech, coarse facial features, relative
macrocephaly, brachycamptodactyly of fifth fingers, and
early-onset cerebellar atrophy (Table 1).21 To perform ge-612 The American Journal of Human Genetics 95, 611–621, Novembnetic analysis aimed at identifying the causal mutation,
informed consents were obtained for all of the parents, pro-
bands, and siblings according to protocols approved by the
ethical review committees at Great Ormond Street Hospital
andCoimbraHospitalCentre. Specificparental consentwas
also given for the use of all of the clinical data and facial
photographs included in this manuscript. The family waser 6, 2014
Figure 2. Identification of SNX14 Mutations in Three Affected Families
(A) Pedigrees of the three families showing genotypes in tested individuals.
(B) Sequence traces for families 1 and 3 show pointmutations in genomic DNA (top trace, mutant; bottom trace, wild-type). For family 2,
the sequence trace spans the deletion breakpoint, in genomic DNA, and indicates the location of the breakpoints within two Alu repeats
in the schematic diagram of the SNX14 locus shown in (C) (see also Figure S1 for further details).
(C) Schematic representation of part of the SNX14 genomic locus (top) and the SNX14 protein (bottom) indicating the location and
effect of the mutations detected in the three families. The protein consists of two predicted transmembrane domains (TM) at the
N terminus, followed by the PXA domain, RGS domain, conserved PX phosphoinositide binding domain, and PXC domain situated
toward the C terminus. The deletion in family 2 is predicted to remove the RGS and PX domains, whereas the splice site mutation in
family 3 removes part of the PX domain.then investigated by first delineating regions of shared ho-
mozygosity followed by whole-exome sequencing to iden-
tify variants in the implicated regions. Homozygosity map-
pingwas performed on the two parents (III.1 and III.2), two
affected siblings (IV.3 and IV.6), and fourunaffected siblings
(IV.1, IV.4, IV.5, and IV.7) using the InfiniumHDHumanCy-
toSNP-12 BeadChip (Illumina). This revealed 20 candidateThe Americanregions spanning a total of 35,846,704 bp,which contained
450RefSeq and886UCSC transcripts (Table S1 available on-
line). Haplotype analysis of the SNP data defined the largest
homozygous region of ~18 Mb on 6q13-q14 (hg19; chr6:
70,500,118–88,497,536). Exome sequencing of the pro-
band (IV.3) from family 1wasperformedusingAgilent Sure-
Select v.4 and Illumina TruSeq. Enriched libraries wereJournal of Human Genetics 95, 611–621, November 6, 2014 613
Table 1. Clinical Findings in the Affected Individuals
Mutation in SNX14
(RefSeq NM_153816.3)
Family 1 Family 2 Family 3
Total
homoz p.Gln866*
(c.2596C>T)
homoz p.Val369_Leu702del
(c.1108þ1181_21082342del)
homoz
p.Ala603_
Gly632del
(c.1894þ1G>A)
Subject ID IV.3 IV.6 IV.1 IV.2 V.1 V.2 III.2
Sex F F F M F M F 5F, 2M
Present age (years) 26 14 32 16 10 3 23
Growth at Birtha
Gestational age (weeks) 40 34 (twin) U U 40 40 U
Length, cm (centile) 49 (50th) 42 (10th) U U U U U
Weight, g (centile) 3,600 (50th) 2,100 (25th) U U 2,650 (3–10th) 2,800 (10–25th) U
Head circumference, cm
(centile)
35.5 (50th) 32 (50th) U U U 35.5 (90th) U
Growth, Postnatala
Age (years) 22 14.5 29 14 6.7 1.0 22
Height, cm (centile) 155 (10th) 140 (<3rd) U U (91st) 76.1 (<75th) 157.7 (9–25th)
Head circumference
(centile)
56.4 (75–90th) 57.5 (90–97th) 59 (>97th) 55 (50th) 55 (>97th) 49.5 (97th) 56.5 (75–90th)
Neurodevelopment
Intellectual disability severe severe severe severe severe NA moderate
Speech (1st words, years) absent sev impaired (13) absent absent absent absent impaired (3) 5/7
Hypotonia þ þ - þ þ þ þ 6/7
Sitting (age, months) 18 16 very late >36 8 >12 12 18b
Walking with help
(age, months)
þ (24) þ (20) crawls crawls þ (24)  þ (18)c 4/7
Ataxia þ þ wheelchair wheelchair þ NA þ 5/6
Talipes equino-varum þ þ þ U    3/6
Hypo/areflexia þ þ þ þ  NA þ 5/6
Craniofacial Features
Coarse features þ þ þ þ þ þ þ 7/7
Short palpebral fissures þ þ þ þ þ þ  6/7
Fullness of the upper
eyelid
þ þ þ þ þ þ  6/7
Broad/bulbous nose þ þ þ þ þ þ þ 7/7
Broad deep long philtrum þ þ þ þ þ þ  6/7
Thick lip vermilions
(upper þ lower)
þ þ þ þ þ þ þ (lower) 7/7
Skeleton and Limbs
Scoliosis/kyphosis   þ þ    2/7
Brachy/camptodactyly of
5th fingers
þ þ þ þ þ  þ 6/7
Short and broad
finger/toes
þ þ þ þ þ þ (þ) 7/7
Elbow motion limitation þ þ U    þ 3/6
Hearing loss SN þ  SN SN  SN 5/7
(Continued on next page)
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Table 1. Continued
Mutation in SNX14
(RefSeq NM_153816.3)
Family 1 Family 2 Family 3
Total
homoz p.Gln866*
(c.2596C>T)
homoz p.Val369_Leu702del
(c.1108þ1181_21082342del)
homoz
p.Ala603_
Gly632del
(c.1894þ1G>A)
Brain Imaging MRI MRI CT MRI MRI MRI MRI
Age at last evaluation 20 years 7 years U 10 months 4.5 years 9 months 10 years
Cerebellar atrophy þ P þ P þ  þ P  þ P 5/7
Pontine thinning þ  U  þ  (þ) 4/7
Abbreviations and symbols are as follows: þ, positive; , negative/normal; U, data unknown; P, progressive: i.e., two or more sequential scans showed develop-
ment/progression of the cerebellar atrophy; SN, sensorineural, moderate-severe, bilateral; NA, not applicable.
aGrowth measurements: For the Turkish individuals, the charts used for head circumference measurements were described by Evereklioglu et al.19 and Elmali
et al.20 The Portuguese individuals were compared to national charts except for head circumference >36 cm, or where not available, the charts described by Ever-
eklioglu et al.19 were used.
bMedian for sitting age.
cSubject III.2 from family 3 was the only individual who progressed to independent ambulation, which was reached at age 3 years.sequenced on an Illumina HiSeq2000 by Perkin Elmer,
resulting in amean of 663 read depth with 68% of targeted
bases covered at least 13. We sequenced one sample
per lane, aligning the resulting reads to the reference
genome build GRCh37/hg19 using Burrows-Wheeler
Aligner (v.0.5.7) and for variant calling we applied GATK
base quality score recalibration,22 INDEL realignment,
and duplicate removal and performed SNP and INDEL dis-
covery and genotyping across all samples simultaneously
using variant quality score recalibration.23 Variant annota-
tion and interpretation analysis was generated through the
use of Ingenuity Variant Analysis software v.3.0.20140422
from Ingenuity Systems. With the use of filters outlined in
Table S2 designed to pinpoint novel or rare homozygous
damaging variants, we reduced the number of variants
from an initial 159,274 genome wide, to a single likely
causalmutation. This was a unique, homozygous nonsense
variant (c.2596C>T [p.Gln866*]) within SNX14, located at
6q14.3,which iswithin the largest autozygous interval (Fig-
ures 2B and 2C; Table S3). Sanger sequencing using Big Dye
Terminator v.1.1 (Life Technologies) on an ABI 3730
sequencer (Applied Biosystems) confirmed that the muta-
tion was homozygous in both affected sisters and segre-
gated as an autosomal recessive, being heterozygous in
both parents and absent or heterozygous in four unaffected
siblings (Figure 2A). The SNX14 locus generates two
transcripts consisting of either 29 exons encoding the
946 amino acid isoform a (RefSeq NM_153816.2) or 26
exons, lacking exons 14, 23, and 24, encoding a shorter
protein of 893 amino acids known as isoform b (RefSeq
NM_020468.3). Both isoforms share the same four
conserved domains: the PX (phosphoinositide binding,
Phox homology), RGS (regulator of G protein signaling),
PXA (PX-associated domain A), and PXC (PX-associated
domain C) (Figure 2C). The c.2596C>T mutation was
identified within an exon that codes for both transcripts
(exon 26, based on the longer transcript) andwas predicted
to result in a protein truncation that would either re-
move the last 81 amino acids, including part of the PXCThe Americandomain or, alternatively, trigger nonsense-mediated decay
(Figure 2C).
We identified a Turkish consanguineous family (family
2) with four affected individuals sharing similar clinical
features to family 1 (Table 1; Figures 1 and 2A). SNP geno-
typing (as above), revealed 11 regions of homozygosity
shared between all three of the affected individuals avail-
able at the time of mapping (IV.1, IV.2, and V.1), with
the largest (8,056,114 bp) including the interval contain-
ing SNX14 in 6q14.3, being the only autozygous region
in common with family 1 (Table S1). Individual V.1 under-
went exome sequencing at Dasman Diabetes Institute
(Kuwait City, Kuwait) using methodologies as described
for family 1, with 89% of target bases covered at least 13
with an average depth of 333 per base. Using the same
filtering parameters as those for family 1, we were able to
reduce the number of variants from 199,920 to 18 (Table
S2). As examination of these failed to identify any of these
within the regions of shared homozygosity, we decided to
look in more detail at SNX14. Specifically, we viewed the
reads across SNX14 using Integrative Genomics Viewer
(IGV) software (Broad Institute),24 which revealed a homo-
zygous deletion of 9 consecutive exons from exon 13 to 21
(with respect to isoform a) (Figure S1A and Table S4), while
all DNAs sequenced at the same time from unaffected sub-
jects had good read depth for this interval (Figure S1A). The
deletion was confirmed, first noting the lack of PCR ampli-
fication of individual exons from genomic DNAs, then by
testing a series of primers flanking the approximate break-
point position (Figure S1B). The latter strategy allowed
determination of the precise sequence of the junction
fragment. The deletion most likely occurred as a conse-
quence of illegitimate recombination between two Alu-
repeat sequences found in intron 12 and intron 21. This
resulted in a deletion spanning 25,640 bases, described as
c.1108þ1181_21082342del with reference to isoform a
cDNA or hg19 coordinates chr6: 86,255,692–86,230,052
(Figure S1C). In addition, Affymetrix CytoScan 750K array
analysis of the youngest affected individual (V.2) revealed aJournal of Human Genetics 95, 611–621, November 6, 2014 615
Figure 3. SNX14 RNA Expression in Fibroblasts from Affected
and Control Individuals
qRT-PCR showing relative quantification (RQ DDCT method) of
SNX14 expression in affected fibroblasts samples from each family
compared with controls. Both GAPDH and HPRT1 were used as
combined endogenous controls, with RQ calculated using Ste-
pOne analysis software v.2.1 (Life Technologies). Each experiment
was biologically replicated three times with each sample analyzed
in triplicate. Using a two-tailed t test, family 1 individual IV.3
shows a 60% decrease in expression compared to combined con-
trols, where fibroblasts from five different control individuals
have been analyzed (N ¼ 5), **p ¼ 0.009. Family 3 individual
III.2 shows a 51% drop in expression compared to controls, *p ¼
0.05. However, family 2 individual V.1 shows no significant differ-
ence in expression compared to controls, p ¼ 0.74. Error bars
correspond to mean5 SEM.homozygous deletion spanning five consecutive probes
within SNX14, corresponding to the interval described
above (Figure S2). Sanger sequencing of cDNA synthe-
sized from fibroblast mRNA (V.1) confirmed that there
was in-frame splicing between exon 12 and exon 22
(Figure S1D), which is predicted to remove 334 amino
acids (p.Val369_Leu702del) from the full-length protein,
including the entire RGS and PX domains (Figure 2C).
We genotyped all of the available family members using
a PCR-based approach to confirm segregation of the dele-
tion. This revealed that only the four affected individuals
were homozygous for the deletion, although eight unaf-
fected individuals were heterozygous and three were ho-
mozygous for the reference allele (Figure 2A).
We next searched the Great Ormond Street Hospital
Clinical Genetics records to identify affected individuals
based solely on similar features. We performed text
searches of the electronic medical records of all children
known to the Clinical Genetics department using the
terms ‘‘pontocerebellar hypoplasia,’’ ‘‘cerebellar hypopla-
sia,’’ OR ‘‘cerebellar atrophy’’ AND ‘‘hearing loss’’ and
manually examined all sets of notes and clinical photo-
graphs, excluding all affected individuals with an alter-
native diagnosis or with microcephaly. This strategy
identified family 2 (above) and a single further individual
in an unrelated Turkish consanguineous family (family 3)
among more than 50 case subjects matching the pontocer-
ebellar or cerebellar search terms. The individual III.1 from
family 3 (Figure 2A) had cerebellar ataxia, sensorineural
hearing loss, slightly coarse facial features, relative macro-616 The American Journal of Human Genetics 95, 611–621, Novembcephaly, and bilateral fifth finger camptodactyly but gener-
ally had milder features than the other affected individuals
in terms of the radiological degree of cerebellar atrophy
and her motor, intellectual, and speech development (Ta-
ble 1). Sanger sequencing of SNX14 exons and exon-intron
boundaries in III.1 identified a homozygous canonical
splice site mutation (c.1894þ1G>A), which was heterozy-
gous in both parents (Figure 2A). Using mRNA isolated
from peripheral blood lymphocytes, we confirmed in-
frame splicing of exon 18 to exon 20 (isoform a),
completely skipping exon 19 (Figure S3). This was pre-
dicted to result in the deletion of 30 amino acids
(p.Ala603_Gly632del) from within the PX domain
(Figure 2C).
Using fibroblast cDNA, we compared mutant and wild-
type transcript levels using quantitative RT-PCR with
Power SYBR green PCR Master Mix on StepOnePlus Real-
Time PCR Systems (Life Technologies). Compared to con-
trols, we noted significantly reduced levels of expression
in families 1 and 3, whereas levels in family 2 were similar
(Figure 3). To investigate protein levels, SNX14 was
analyzed by immunoblotting (Figure S4). A single band
of ~110 kDa was reproducibly obtained in control fibro-
blasts, but no band was detected in either family 1:IV.6
or 2:V.1. For family 1:IV.6, only a low level of mRNA was
present, and this may produce an unstable or subdetect-
able level of protein. This also ties in with the possibility
of activation of the nonsense-mediated decay pathway.
For family 2:V.1, the deletion removes 112 of the 131
amino acid peptides used to raise the anti-SNX14 antibody.
Therefore, it is conceivable that a truncated protein is pre-
sent but not detectable with this assay. For family 3:III.2, a
protein of slightly lower molecular weight (~107 kDa) is
detected, approximating to the loss of amino acids due to
skipping of exon 19. Collectively, the mutation data are
supportive of a loss of normal biological function for
SNX14.
Therefore, we identified a total of seven affected individ-
uals from three unrelated families who share a distinct
rare syndrome resulting from SNX14 mutations. Neither
point mutation was present in the NHLBI-ESP-EVS 4,870
exomes or in our internal database of 358 exomes. The
Database of Genomic Variants lists 13 unaffected individ-
uals who are heterozygous for 7 different but overlapping
microdeletions of ~31–130 kb (n ¼ 1/2,026; 1/2,026;
7/2026; 1/1,557; 1/443; 1/17,421; 1/17,421)25–28 and a sin-
gle 40 kb microduplication (n ¼ 1/2,026),25 all involving
parts of the SNX14 locus. However, a review of 4,500
GOSH children screened using the Affymetrix 750K array
did not identify any further individuals, other than from
family 2, who carry deletions or duplications that included
SNX14.
Only five individuals with microdeletions involving
SNX14 are well described in the literature.29–32 Two of
these are included in DECIPHER, which lists seven individ-
uals with intellectual disability and other various defects
who have large (~5 Mb) heterozygous deletions, and aer 6, 2014
further two with duplications that encompass SNX14 and
other nearby genes. Of these, only the two unrelated indi-
viduals described by Wentzel et al.,31 who have large inter-
stitial deletions (8.7 Mb and 4.5 Mb) containing SNX14
and three neighboring genes, have some phenotypic simi-
larity to our affected individuals. In particular this includes
the presence of ID, similar facial dysmorphic features,
hearing loss, and macrocephaly. Additionally, one of these
individuals had camptodactyly and limited movement of
the elbows. None of them were reported to have cerebellar
atrophy or ataxia, but both of them had walking diffi-
culties and one was reported to have dyspraxia. Currently,
we cannot exclude the presence of a second, SNX14-spe-
cific point mutation on the non-CNV-carrying chromo-
some in these cases.
In an attempt to further extend the phenotypic spec-
trum associated with SNX14 mutations, we investigated
whole-exome sequencing data obtained for a series of 36
individuals with idiopathic pontocerebellar hypoplasia,
and 168 from dominant and recessive families with idio-
pathic cerebellar ataxia, of which 138 were recessive/early
onset or no family history. However, no likely causal vari-
ants or CNVs affecting SNX14 were identified. These data
suggest that autosomal-recessive SNX14 mutations are
associated with a narrow clinical spectrum. The presence
of coarse faces and the absence of microcephaly and epi-
lepsy are distinctive features within this group of condi-
tions, confirming our findings reported in the description
of the first family.21 Additionally, sensorineural hearing
loss and camptodactyly of fifth fingers seem also to be
prevalent (Table 1). Nevertheless, it should be noted
that clinical recognition is challenging in infants because
dysmorphic features, cerebellar involvement, ID, speech
impairment, and ataxia are progressive and absent at an
early age. Neuroradiological scans performed in the first
years of life appeared normal but later were characterized
by a globally small cerebellum (Table 1, Figure 1). Both
the hemispheres and vermis are affected and there is sepa-
ration of the folia indicating atrophy rather than hypopla-
sia (Figure 1). Evidence for slight pontine thinning was
seen in older patients. This phenotype is significantly
different from the pontocerebellar hypoplasias group of
conditions, which are usually more severe, with prenatal-
onset hypoplasia/atrophy of cerebellum and pons, associ-
ated with progressive microcephaly and seizures.
SNX14 is a member of the large family of sorting nexin
proteins but it has only recently been investigated for
its tissue distribution and cellular function. The earliest
report describes Snx14 mRNA expression using an
in vitro motoneuron selection method.33 Mice in this
study were found to have the highest levels of Snx14
mRNA expression at E12.5, restricted to neuronal lineages
such as the spinal cord. Expression in the brain was seen in
the ventral ventricular region, the floor plate, V (trigemi-
nal) and VIII (vestibulocochlear) cranial ganglia, the
saccule of the inner ear, the developing pituitary gland,
and eye. In general, mRNA distribution was describedThe Americanas colocalizing with Islet-1 expression, including Islet-1-
positive motoneurons.33 Furthermore, Northern blot anal-
ysis in different adult mouse tissues revealed Snx14
expression in cerebellum and hippocampus and at much
lower levels in cortex, muscle, liver, lung, and heart.33
We investigated SNX14 mRNA expression in human
fetal tissue using RT-PCR and found it to be ubiquitously
present in all tissues analyzed, including heart, skin, brain,
kidney, bone, liver, eye, and placenta (Figure S5). The Allen
Brain Atlas reports in situ hybridization for the p56 mouse
brain, where the highest levels of Snx14 expression were
found in the granule and Purkinje cell layers of the cere-
bellar cortex but also in the hippocampus (granule layers
and dentate gyrus) and the piriform. This was supported
by data from both the human UK Brain Expression Con-
sortium (UKBEC) and the Human Brain Transcriptome
database.34,35 SNX14 is expressed in all brain regions,
with generally increasing levels during prenatal develop-
ment and then plateauing. Interestingly, the pattern the
cerebellum is the region where SNX14 is most highly ex-
pressed and transcript levels continue to increase through
postnatal life until adult (UKBEC data, Figure S6). Most
recently, Huang et al.36 described mouse SNX14 levels as
being high in brain, testis, and lung, similarly showing
an increase in cerebellar levels from embryonic to post-
natal stages (E16.5–p63). Despite a broadly distributed
spatiotemporal pattern, which might suggest function in
many tissues, high levels in the central nervous system
and particularly cerebellum correspond to the described
phenotype (with internal organs spared), particularly the
cerebellar atrophy seen in affected individuals from all
three families presented here.
To date there are 49 mammalian proteins known to
contain a PX domain and the majority of these are classi-
fied as sorting nexin proteins.37 The PX domain binds to
phosphoinositides (PtdIns3P) on the cytoplasmic leaflets
of various organelles and it defines both subcellular locali-
zation and function of different PX domain-containing
proteins including endosomal sorting and trafficking.37
Mutations in the p47phox subunit of NADPH oxidase are
known to cause autosomal-recessive chronic granuloma-
tous disease (MIM 233700),38 whereas SNX27 has been
indirectly linked to synaptic dysfunction in Down syn-
drome through impaired transcriptional regulation,39
and recently SNX10 mutations have been demonstrated
to cause a nonsyndromic autosomal-recessive form of
osteopetrosis (MIM 615085), an osteoclast-related bone
disease.40
Based on predicted domain structure, SNX14 is classified
within the PXA-RGS-PX-PXC subfamily along with
SNX13, SNX19, and SNX25.41 Like SNX13, SNX14 also
contains a putative double transmembrane domain
including a short cytoplasmic leader sequence and an
RGS domain, implying they share a similar function
(Figure 2C). The RGS domain of SNX13 can bind to and in-
crease the GTPase activity of the G-alphas (Gas) subunit of
G-protein coupled receptors (GPCRs). Mediated by the PXJournal of Human Genetics 95, 611–621, November 6, 2014 617
Figure 4. Electron Micrographs of Skin
Biopsy and Cultured Fibroblasts
(A) Control cultured fibroblast at 8003
magnification.
(B and C) Skin section from family 3 indi-
vidual III.2 at 8003 magnification.
(B) In the epidermis, there was mild
hyperkeratosis with keratinocytes showing
increased vacuolation, containing fine
nonspecific granular material (arrows).
(C) In the dermis, collagen and elastic
tissue had a normal appearance and distri-
bution with infrequent vacuoles in the
fibroblasts.
(D–F) Cultured fibroblasts from family
1 individual IV.6, family 2 individual
V.1, and family 3 individual III.2, respec-
tively, at 8003 magnification. The cells
showed numerous cytoplasmic vacuoles,
often containing dense staining material
suggestive of lipid degeneration. Same
cells at 3,0003 magnification shown in
(D0)–(F0). Vacuoles contained granular
material or multilamellar bodies or were
empty (see white and black arrows for
examples).domain, this activity can occur at the endosome, allowing
Gas signal attenuation at the interface with this protein
sorting and degradation pathway.42,43 Loss of functional
SNX13 in the mouse resulted in dramatically altered endo-
cytic/lysosomal compartmentalization in visceral yolk sac
endoderm, with abnormal localization of several endocytic
markers and with the appearance of abundant autophagic
vacuoles.44
A role for SNX14 in endosomal sorting and the regula-
tion of protein degradation is supported by recent analyses
of the prenatal human brain transcriptome.45 Weighted
gene coexpression network analysis (WGCNA) was used
to group genes expressed within mid-fetal human
neocortex into modules in an unsupervised manner.46
This approach is extremely useful in identifying modules
of biologically related genes that are not just coexpressed,
but coregulated.47 This method was applied to predict
that SNX14 is highly coexpressed within a module (C25,
black),45 which is significantly enriched for genes involved
in cellular protein metabolism (Gene ontology term
GO:0044267~cellular protein metabolic process, Bonfer-
roni-corrected p value¼ 9.183 105) and vesicle-mediated
transport between the ER and Golgi (GO:0006888~ER to
Golgi vesicle-mediated transport, Bonferroni-corrected p
value ¼ 7.59 3 104).
This prompted us to examine cellular ultrastructural
morphology in skin biopsy material and fibroblast cell
lines, using a JEOL 1400 transmission electron microscope
(Figure 4). Compared to control samples, the skin biopsy
showed an adequate epithelial layer with a moderate de-
gree of hyperkeratosis and occasional apoptotic bodies.618 The American Journal of Human Genetics 95, 611–621, NovembVacuoles with fine nonspecific granular material were
identified in keratinocytes (Figure 4B). In the dermis,
collagen and elastic tissue had a normal appearance and
distribution. Fibroblasts demonstrated infrequent vacu-
oles with granular material and rare electron-dense lami-
nated inclusions suggestive of lipid degeneration. No
sweat glands were available for assessment and small
myelinated and unmyelinated nerves were unremarkable.
Next, we investigated ultrathin sections from cultured skin
fibroblasts from one affected individual from each of the
three families and control subjects. Affected fibroblasts
were found to have frequent cytoplasmic vacuolation
with electron-dense material of variable morphology
including some with evidence of lamella structure as
seen in multilamellar bodies (Figures 4D–4F). Interestingly,
a proportion of fibroblasts from affected individuals but
not control subjects immunostain positive for p62 in a
granular pattern (Figure S7), which might suggest a defect
in the autophagy pathway, as seen in many neurodegener-
ative and neurodevelopmental disorders.48 Interestingly,
cultured fibroblasts from individuals with MSS similarly
contain numerous cytoplasmic electron-dense, sometimes
multilamellar inclusion, bodies in both individuals with
and without SIL1 mutations.1 MSS and the SNX14 pheno-
type share the presence of ID, cerebellar atrophy, hypoto-
nia, and ataxia. Therefore SNX14 should be screened
in MSS-like individuals not carrying an SIL1 mutation,
especially in those without microcephaly, cataracts, or
myopathy (creatinine kinase levels were in the normal
range for the four individuals tested who have SNX14
mutations).er 6, 2014
Zheng et al.44 reported that heterozygous Snx13þ/mice
do not have an obvious phenotype, whereas Snx13/
mice die between E10.5 and E14.5. Mutants are small
and have exencephaly and abnormal cephalic vasculariza-
tion, presumably in response to defective nutrient uptake
and transport, particularly in the yolk sac endoderm,
which could account for embryonic developmental delay.
Snx14 knockdown studies using lentiviral shRNA, specif-
ically in mouse cortical pyramidal neurons, were recently
reported.36 Despite incomplete (60%) knockdown, signifi-
cantly reduced intrinsic excitability and synaptic function
was recorded. The study of Huang et al.36 also reported
Snx14 to be maternally imprinted but suggest that this
might be mouse specific. Our data support this because un-
affected heterozygous individuals inherit the mutation on
either the maternal or paternal allele (Figure 2A).
In conclusion, in terms of a potential mechanism there
is a compelling case for a role of SNX14 in synaptic trans-
mission.40 Synaptic dysfunction is well known to be impli-
cated in neurodevelopmental disorders associated with
ID49 and this may underlie the pathogenesis of SNX14mu-
tations. Other genes coding RGS proteins, especially of the
Rho GTPase family, cause ID syndromes and have a crucial
role in synaptic structure/function.50 Interestingly, a sig-
nificant phenotypic overlap is seen with OPHN1 encoding
a Rho-GAP protein, in which mutations cause an X-linked
form of syndromic ID typically associated with cerebellar
abnormalities, dysmorphic (often coarse) facial features,
and sometimes macrocephaly.5,50 Overall, our results
implicate an essential role for SNX14 with the breakdown
and recycling of cellular components in human cerebellar
development and maintenance.Supplemental Data
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Figure S1: Mapping the genomic breakpoints of the 9 exon deletion in 
Family 2. A) IGV screen capture showing exome sequence reads within the 
SNX14 locus of patient V.1 (Family 2) and two controls sequenced on the 
same run. The red arrow shows the region of 9 adjacent exons with no 
sequence reads indicating a homozygous deletion. B) Sanger sequence 
across the deletion breakpoint in genomic DNA of the same patient and a 
schematic diagram of the locus to show the position of the flanking Alu/Sine 
repeat sequences. The arrow represents the breakpoint by indicating the first 
base of the second Alu/Sine sequence. C) SNX14 genomic sequences from 
Introns 12 and 21 aligned against the Alu/Sine repeat sequence using 
ClustalW show the origin of the breakpoint. In the deletion, blue and red 
sequences are contiguous (as seen in B). D) Sanger sequence of cDNA from 
patient V.1 and a schematic diagram illustrate that exon 12 splices to exon 22. 
 
 
 
 
 
  
 
Figure S2. Copy number analysis on Family 2 patient V.2 using the 
Affymetrix CytoScan 750K array. The minimum deleted region is defined by 
CGH probes marked B (86,233,056) and C (86,252,888); the maximum 
deleted region is defined by A (86,223,224) to D (86,257,848). 
 
 
 
  
 
 
 
 
 
 
 
 
 Figure S3. SNX14 cDNA sequences from Family 3, 
demonstrating that the splice site variant results in skipping of exon 19. 
  
 
Figure S4. SNX14 levels in affected and control fibroblasts were 
detected by western blotting. SNX14 levels in cases and controls were 
analysed by immuno-blotting total protein extracted from fibroblast cells using 
an anti-SNX14 antibody (1:500; Sigma HPA017639). Protein loading is shown 
using the image obtained from a ChemiDoc MP imaging system with Mini-
PROTEAN TGX Stain-Free precast gels (Bio Rad, UK). The Image data was 
analysed using Image Lab version 4.1 (Bio Rad, UK). A representative blot of 
three independent experiments with similar results is shown. 
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Figure S5. RT-PCR of SNX14 expression in fetal tissues. Tissues include 
heart, skin, brain, kidney, bone, liver, eye and placenta. Where available, 
tissues were used from two separate fetal samples.  
 
Figure S6. Human brain SNX14 and SNX13 transcript analysis. Top: 
Spatio-temporal SNX14 (left) and SNX13 (right) transcriptomes of the human 
brain using data from the Human Brain Transcriptome (HBT) database.34 This 
study assessed 6 brain regions (cerebellar cortex (CBC), mediodorsal nucleus 
of the thalamus (MD), striatum (STR), amygdale (AMY), hippocampus (HIP) 
and the neocortex (NCX)) over 15 periods of the human pre and post-natal 
development. These data were generated from Affymetrix Human Exon 1.0 
ST Arrays performed on 1,340 tissue samples collected from 57 developing 
and adult post-mortem brains of clinically unremarkable donors representing 
males and females of multiple ethnicities. Levels of SNX14 increase 
throughout the brain during fetal development, before plateauing. In the 
cerebellum, expression continues to rise during postnatal life reaching its 
highest level during adulthood. Contrast with SNX13, which decreases 
towards birth, then more modestly increases in most brain regions.  Bottom: 
Regional distribution of SNX14 (left) and SNX13 (right) expression in human 
brain. Box plots of mRNA levels from 10 brain regions (left to right: the 
cerebellum (CRBL, n=130), frontal cortex (FCTX, n=127), hippocampus 
(HIPP, n=122), medulla (specifically inferior olivary nucleus, MEDU, n=119), 
occipital cortex (specifically primary visual cortex, OCTX, n=129), putamen 
(PUTM, n=129), substantia nigra (SNIG, n=101), temporal cortex (TCTX, 
n=119), thalamus (THAL, n=124), and intralobular white matter (WHMT, 
n=131)) are based on microarray experiments and plotted on a log2 scale (y-
axis). Material and methods were as previously reported.34,35 In brief, these 
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samples originate from 134 adult individuals from the UK Brain Expression 
Consortium and were profiled on 1231 Affymetrix Human Exon 1.0 ST arrays. 
Whiskers extend from the box to 1.5 times the inter-quartile range.  	  
  
  
 
Figure S7. p62 immunostaining of fibroblasts suggest defective 
autophagy. Cultured fibroblast cell suspensions from two patients and two 
controls were centrifuged to prepare smears using a Thermo Scientific 
Cytospin. A p62 antibody (1:500 dilution, BD Bioscience), was used to 
investigate the autophagy pathway, employing standard protocols on a Leica 
BOND MAX immunostainer. Many cells in the Family 3:III.2 sample were 
strongly positive with a granular appearance. A smaller number of positive 
cells with the same distinct morphology were seen in Family 2:V.1 fibroblasts. 
For the controls, one sample was negative, whilst the other C(2) showed a 
higher level of background staining without the granular morphology.  
Table S1. Regions of homozygosity shared between affected individuals 
in Families 1 and 2. 
 
Family	  1	  (II.3	  +II.6)	   Family2	  (IV.1+IV.2+V.1)	  
Chr	   Start	   End	   Size	  (bp)	   Chr	  	   Start	   End	   Size	  (bp)	  
1	   49215178	   50025098	   809920	   2	   167634200	   168219266	   585066	  
2	   14334445	   15105276	   770831	   3	   87497605	   87550022	   52417	  
2	   98451967	   98972624	   520657	   3	   87550022	   98418129	   767324	  
4	   52732440	   53571137	   838697	   3	   137516694	   138461351	   944657	  
4	   59336192	   60143936	   807744	   5	   122710247	   123328850	   618603	  
5	   172038414	   173762787	   1724373	   6	   80467595	   88523709	   8056114	  
6	   44642275	   45480198	   837923	   6	   103137113	   103711271	   574158	  
6	   67688533	   69401011	   1712478	   8	   47965922	   48816429	   850507	  
6	   70500118	   88497536	   17997418	   9	   88677735	   89150849	   473114	  
6	   91529972	   91695918	   165946	   11	   32236138	   34302743	   2066605	  
6	   107328569	   108056760	   728191	   17	   19741141	   20387780	   646639	  
8	   89115291	   89766139	   650848	   	   	   	   	  
8	   115018872	   115580787	   561915	   	   	   	   	  
8	   119514102	   120079494	   565392	   	   	   	   	  
8	   144993574	   145971916	   978342	   	   	   	   	  
11	   8403642	   9363862	   960220	   	   	   	   	  
14	   103823162	   104381937	   558775	   	   	   	   	  
15	   56763412	   57589554	   826142	   	   	   	   	  
15	   72095961	   73111070	   1015109	   	   	   	   	  
21	   43733078	   46548861	   2815783	   	   	   	   	  
 
The largest shared region in each family, which is the only common region 
between the two families and contains the SNX14 locus, is highlighted in 
yellow. Nucleotide positions are from the hg19 assembly.  
Table S2: Filtering parameters used in Ingenuity Variant Analysis. 
 
Data corresponds to individual II.3 in Family 1 and V.1 in Family 2. 
  
Number of 
variants 
(Family 1)
Number of 
variants 
(Family 2)
Keep Exclude
159,274 199,920 All variants
141,401 171,260
Call quality ≥ 20, Read Depth ≥ 10 AND 
outside top 0.2% most exonically variable 100 
base windows in healthy public genomes (1000 
genomes) AND outside top 1.0% most 
exonically variable genes 
25,032 31,313
Observed with allele frequency ≥ 0.1% in the 1000 genomes project 
or the public Complete Genomics genomes or NHLBI ESP exomes
1,096 1,326
Pathogenic,	  Possibly	  Pathogenic	  OR	  
established	  gain	  of	  function	  in	  the	  literature	  
OR	  inferred	  activating	  mutations	  by	  Ingenuity	  
OR	  predicted	  gain	  of	  function	  by	  BSIFT	  OR	  
Frameshift,	  in-­‐frame	  indel,	  or	  stop	  codon	  
change	  OR	  Missense	  and	  not	  predicted	  to	  be	  
innocuous	  by	  SIFT	  or	  Polyphen-­‐2	  OR	  disrupt	  
splice	  site	  upto	  2.0	  bases	  into	  intron
2 22 Homozygous in case Homozygous or heterozygous in ≥1 control exome (N=6)
1 18
within 1 hop upstream and that are known or 
predicted to affect: mental retardation, 
developmental delay or diseases consistent with 
these phenotypes OR genes within 1 hop 
downstream of them
Table S3 RefSeq genes in the Family 1 region of shared homozygosity 
chr6:70500118-88497536, showing mean coverage and % bases covered 
at >1x and >10x read depth. 
 
Gene	   mean	  coverage	  
%	  >1x	   %	  >10x	  
LMBRD1	   71	   98	   96	  
COL19A1	   66	   96	   94	  
COL9A1	   90	   99	   98	  
FAM135A	   58	   88	   83	  
C6orf57	   89	   100	   93	  
SMAP1	   64	   98	   91	  
B3GAT2	   33	   88	   80	  
OGFRL1	   70	   99	   87	  
RIMS1	   77	   92	   89	  
KCNQ5	   85	   92	   90	  
KHDC1L	   67	   100	   100	  
KHDC1	   50	   94	   74	  
C6orf147	   1	   42	   0	  
DPPA5	   183	   100	   95	  
KHDC3L	   65	   96	   92	  
OOEP	   33	   100	   93	  
DDX43	   92	   99	   93	  
MB21D1	   72	   100	   100	  
MTO1	   82	   96	   87	  
EEF1A1	   27	   76	   41	  
SLC17A5	   65	   97	   84	  
CD109	   76	   98	   96	  
COL12A1	   84	   99	   96	  
COX7A2	   45	   100	   90	  
TMEM30A	   52	   89	   86	  
FILIP1	   99	   75	   72	  
SENP6	   76	   96	   94	  
MYO6	   56	   95	   94	  
IMPG1	   67	   96	   93	  
HTR1B	   77	   81	   83	  
IRAK1BP1	   78	   91	   90	  
PHIP	   86	   98	   95	  
HMGN3	   39	   99	   96	  
LCA5	   60	   76	   70	  
SH3BGRL2	   19	   83	   53	  
RNY4	   0	   0	   0	  
C6orf7	   0	   30	   0	  
ELOVL4	   51	   87	   82	  
TTK	   64	   95	   94	  
BCKDHB	   68	   92	   90	  
FAM46A	   89	   76	   73	  
IBTK	   92	   96	   93	  
TPBG	   16	   41	   15	  
UBE3D	   77	   97	   95	  
DOPEY1	   78	   97	   96	  
PGM3	   102	   97	   88	  
RWDD2A	   50	   95	   65	  
ME1	   61	   96	   84	  
PRSS35	   19	   46	   21	  
SNAP91	   46	   97	   85	  
RIPPLY2	   40	   100	   97	  
CYB5R4	   66	   98	   95	  
MRAP2	   51	   83	   58	  
CEP162	   92	   95	   94	  
TBX18	   37	   92	   79	  
NT5E	   85	   91	   84	  
SNX14	   77	   99	   89	  
SYNCRIP	   70	   86	   72	  
SNHG5	   11	   55	   23	  
HTR1E	   95	   50	   48	  
CGA	   19	   60	   54	  
ZNF292	   47	   98	   96	  
GJB7	   25	   54	   16	  
SMIM8	   27	   43	   38	  
C6orf163	   72	   100	   92	  
C6orf164	   9	   61	   46	  
C6orf165	   64	   92	   91	  
SLC35A1	   65	   94	   92	  
RARS2	   81	   100	   96	  
ORC3	   66	   100	   98	  
AKIRIN2	   27	   87	   75	  
Average	   60	   86	   77	  
 
  
Table S4 Family 2 V.1 exome sequencing coverage of SNX14 showing 
percentage coverage at >1x or >10x sequence reads 
 
Target % >1x % >10x exon 
6:86215215-86215723 100 90.4 SNX14_exon29 
6:86216951-86217007 100 100 SNX14_exon28 
6:86217686-86217777 100 100 SNX14_exon27 
6:86223518-86223613 100 100 SNX14_exon26 
6:86223788-86223952 100 86.7 SNX14_exon25 
6:86224224-86224347 100 100 SNX14_exon24 
6:86227474-86227593 100 100 SNX14_exon23 
6:86227726-86227766 100 100 SNX14_exon22 
6:86235844-86235955 0 0 SNX14_exon21 
6:86237980-86238080 0 0 SNX14_exon20 
6:86239910-86239993 0 0 SNX14_exon19 
6:86243317-86243518 0 0 SNX14_exon18 
6:86246510-86246642 0 0 SNX14_exon17 
6:86248556-86248582 0 0 SNX14_exon16 
6:86251703-86251761 0 0 SNX14_exon15 
6:86252900-86253024 58.4 0 SNX14_exon14 
6:86253323-86253478 0 0 SNX14_exon13 
6:86256830-86256944 100 100 SNX14_exon12 
6:86257035-86257115 100 100 SNX14_exon11 
6:86257224-86257268 100 100 SNX14_exon10 
6:86258019-86258094 100 100 SNX14_exon9 
6:86259441-86259597 100 81.5 SNX14_exon8 
6:86267694-86267778 100 100 SNX14_exon7 
6:86275050-86275137 100 100 SNX14_exon6 
6:86277252-86277295 100 100 SNX14_exon5 
6:86281855-86281933 100 100 SNX14_exon4 
6:86282016-86282092 100 100 SNX14_exon3 
6:86283976-86284096 100 100 SNX14_exon2 
6:86303297-86303629 91 57.1 SNX14_exon1 
Average 71 66   
Average excl del 
exons 100 96   
 
